MAG
REGN icon

MRA Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

MRA Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-590
Closed -$420K – 146
2024
Q4 		$420K Buy
590
+157
+36% +$132K 0.22% 56
2024
Q3 		$455K Buy
+433
New +$482K 0.25% 53
2024
Q1 		– Sell
-287
Closed -$252K – 116
2023
Q4 		$252K Buy
+287
New +$236K 0.17% 74
2021
Q1 		– Sell
-689
Closed -$333K – 113
2020
Q4 		$333K Buy
+689
New +$372K 0.33% 65

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MRA Advisory Group's REGN Position: Q1 2025 in Review

MRA Advisory Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 590 shares — an estimated $420K sold.

MRA Advisory Group first reported a position in REGN in Q4 2020 and held it in 4 quarters. The position peaked at $455K in Q3 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • MRA Advisory Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • MRA Advisory Group sold 590 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $420K.
  • MRA Advisory Group first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • MRA Advisory Group's Regeneron Pharmaceuticals position peaked at $455K in Q3 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on MRA Advisory Group's 13F filing for Q1 2025, filed 11 Apr 2025.